^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    CANCER:

    Colon Cancer

    Related cancers:
    Apply
    Safety and Effectiveness Study of Pre-operative Artesunate in Stage II/ III Colorectal Cancer (NeoART-M) (NCT07095309)
    Phase 2
    Metanoic Health Ltd.
    Not yet recruiting
    Last update posted :
    07/31/2025
    Initiation :
    08/15/2025
    Primary completion :
    08/30/2032
    Completion :
    07/31/2033
    KRAS • BRAF
    |
    BRAF mutation
    The Effect of Aerobic Exercise on Selective Biomarkers of Patients With Cancer (NCT07048847)
    Phase N/A
    Izmir Bakircay University
    Completed
    Last update posted :
    07/03/2025
    Initiation :
    09/15/2022
    Primary completion :
    08/15/2023
    Completion :
    12/01/2023
    LEP
    Rimegepant Combined With PD-1 in Liver Metastasis Colorectal Cancer Patients (NCT06999252)
    Phase 2
    Fudan University
    Not yet recruiting
    Last update posted :
    05/31/2025
    Initiation :
    07/01/2025
    Primary completion :
    12/01/2028
    Completion :
    06/01/2029
    PD-L1
    A Clinical Study of MK-1084 With Targeted Therapy and Chemotherapy in People With Colorectal Cancer (MK-1084-012/KANDLELIT-012) (NCT06997497)
    Phase 3
    Merck Sharp & Dohme LLC
    Not yet recruiting
    Last update posted :
    05/30/2025
    Initiation :
    07/17/2025
    Primary completion :
    08/27/2029
    Completion :
    06/29/2031
    KRAS
    |
    Avastin (bevacizumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • leucovorin calcium • MK-1084 • levoleucovorin calcium
    Effect of Lidocaine or Dexamethasone on Cancer Immune Response- the PILDI Study (NCT06923787)
    Phase 3
    Institute of Oncology Ljubljana
    Not yet recruiting
    Last update posted :
    04/11/2025
    Initiation :
    11/01/2025
    Primary completion :
    05/01/2027
    Completion :
    05/01/2028
    CXCL8
    Combination Chemotherapy, Bevacizumab, and/or Atezolizumab in Treating Patients With Deficient DNA Mismatch Repair Metastatic Colorectal Cancer, the COMMIT Study (NCT02997228)
    Phase 3
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    01/19/2018
    Primary completion :
    06/01/2027
    Completion :
    06/01/2027
    PD-L1 • MSI • MLH1 • MSH6 • MSH2
    |
    PD-L1 expression • BRAF V600E • MSI-H/dMMR
    |
    Avastin (bevacizumab) • Tecentriq (atezolizumab) • 5-fluorouracil • oxaliplatin • Aybintio (bevacizumab biosimilar) • leucovorin calcium • Mvasi (bevacizumab-awwb) • Vegzelma (bevacizumab-adcd) • Avzivi (bevacizumab-tnjn) • Zirabev (bevacizumab-bvzr) • Jobevne (bevacizumab-nwgd) • fluorouracil topical • Airuituo (bevacizumab biosimilar) • Beianting (bevacizumab biosimilar) • Boyounuo (bevacizumab biosimilar) • GB222 (bevacizumab biosimilar) • Hanbeitai (bevacizumab biosimilar) • Vasforda (bevacizumab biosimilar)
    A Phase I/II Study of Combination Immunotherapy for Advanced Cancers Including HPV-Associated Malignancies, Small Bowel, and Colon Cancers (NCT04708470)
    Phase 1/2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/05/2021
    Primary completion :
    12/01/2025
    Completion :
    12/01/2026
    PD-L1 • CD4
    |
    PD-L1 negative
    |
    Jingzhuda (entinostat) • bintrafusp alfa (M7824) • PDS01ADC
    Combination Chemotherapy With or Without Atezolizumab in Treating Patients With Stage III Colon Cancer and Deficient DNA Mismatch Repair (NCT02912559)
    Phase 3
    National Cancer Institute (NCI)
    Active, not recruiting
    Last update posted :
    02/24/2025
    Initiation :
    10/16/2017
    Primary completion :
    04/02/2025
    Completion :
    04/02/2025
    MLH1 • MSH6 • MSH2 • CD4
    |
    MSI-H/dMMR
    |
    Tecentriq (atezolizumab) • Zelboraf (vemurafenib) • 5-fluorouracil • Cotellic (cobimetinib) • oxaliplatin • leucovorin calcium • fluorouracil topical
    Testing a Combination of Vaccines for Cancer Prevention in Lynch Syndrome (NCT05419011)
    Phase 2
    National Cancer Institute (NCI)
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    05/08/2023
    Primary completion :
    02/01/2027
    Completion :
    02/01/2027
    MLH1 • MSH6 • MSH2 • EPCAM
    |
    Anktiva (nogapendekin alfa inbakicept-pmln) • Tri-Ad5
    COLON ERDERLY LOW DOSE (CELOW) (NCT06840977)
    Phase N/A
    Matteo Clavarezza
    Not yet recruiting
    Last update posted :
    02/21/2025
    Initiation :
    04/01/2025
    Primary completion :
    03/31/2026
    Completion :
    03/31/2026
    BRAF
    A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer (MOUNTAINEER-03) (NCT05253651)
    Phase 3
    Seagen Inc.
    Recruiting
    Last update posted :
    02/21/2025
    Initiation :
    10/24/2022
    Primary completion :
    04/03/2026
    Completion :
    07/27/2029
    HER-2
    |
    RAS wild-type
    |
    Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium